The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Giuseppe Curigliano

Division of Medical Oncology

Istituto Europeo di Oncologia

Via Ripamonti 435

20141 Milano

[email]@ieo.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Medical Oncology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano. 2001 - 2012
  • Department of Medicine, Division of Medical Oncology, Milano, Italy. 2002 - 2011
  • Department of Medicine, Clinical Pharmacology and New Drugs Development Unit, Division of Experimental Oncology, Laboratory of Experimental Immunology, Italy. 2006 - 2008
  • Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy. 2007

References

  1. Targeting the subtypes of breast cancer: rethinking investigational drugs. Curigliano, G., Locatelli, M., Fumagalli, L., Brollo, J., Munzone, E., Nolé, F., Criscitiello, C., Goldhirsch, A. Expert. Opin. Investig. Drugs (2012) [Pubmed]
  2. Cancer-testis antigen expression in triple-negative breast cancer. Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A.A., Bagnardi, V., Spagnoli, G.C., Neville, A.M., Nolè, F., Rotmensz, N., Goldhirsch, A. Ann. Oncol. (2011) [Pubmed]
  3. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. Curigliano, G., Goldhirsch, A. J. Natl. Cancer Inst. Monographs (2011) [Pubmed]
  4. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Curigliano, G., Mayer, E.L., Burstein, H.J., Winer, E.P., Goldhirsch, A. Prog. Cardiovasc. Dis (2010) [Pubmed]
  5. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., Zurrida, S., Nolè, F., Goldhirsch, A. J. Clin. Oncol. (2009) [Pubmed]
  6. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. Curigliano, G., Spitaleri, G., Magni, E., Lorizzo, K., De Cobelli, O., Locatelli, M., Fumagalli, L., Adamoli, L., Cossu Rocca, M., Verri, E., De Pas, T., Jereczek-Fossa, B., Martinelli, G., Goldhirsch, A., Nolè, F. J. Chemother (2009) [Pubmed]
  7. Immunizing against breast cancer: a new swing for an old sword. Curigliano, G., Locatelli, M., Fumagalli, L., Goldhirsch, A. Breast (2009) [Pubmed]
  8. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Curigliano, G., Spitaleri, G., Fingert, H.J., de Braud, F., Sessa, C., Loh, E., Cipolla, C., De Pas, T., Goldhirsch, A., Shah, R. Eur. J. Cancer (2008) [Pubmed]
  9. Immunology and breast cancer: therapeutic cancer vaccines. Curigliano, G., Rescigno, M., Goldhirsch, A. Breast (2007) [Pubmed]
  10. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Curigliano, G., De Braud, F., Teresa Sandri, M., Renne, G., Zorzino, L., Scardino, E., Rocco, B., Spitaleri, G., De Pas, T., Noberasco, C., Nolè, F., Verweij, F., Matei, V., De Cobelli, O. Anticancer. Drugs (2007) [Pubmed]
  11. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Curigliano, G., Spitaleri, G., Dettori, M., Locatelli, M., Scarano, E., Goldhirsch, A. Expert. Rev. Anticancer. Ther (2007) [Pubmed]
  12. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Curigliano, G., Pelosi, G., De Pas, T., Renne, G., De Cobelli, O., Manzotti, M., Spitaleri, G., de Braud, F. Prostate (2007) [Pubmed]
  13. Breast cancer vaccines: a clinical reality or fairy tale?. Curigliano, G., Spitaleri, G., Pietri, E., Rescigno, M., de Braud, F., Cardillo, A., Munzone, E., Rocca, A., Bonizzi, G., Brichard, V., Orlando, L., Goldhirsch, A. Ann. Oncol. (2006) [Pubmed]
  14. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. Curigliano, G., Rigo, R., Colleoni, M., Braud, F.D., Nole, F., Formica, V., Orlando, L., Cinieri, S., Torrisi, R., Cardillo, A., Peruzzotti, G., Medici, M., Ardito, R., Minchella, I., Goldhirsch, A. Clin. Breast Cancer (2004) [Pubmed]
  15. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Curigliano, G., Colleoni, M., Renne, G., Mazzarol, G., Gennari, R., Peruzzotti, G., de Braud, E., Robertson, C., Maiorano, E., Veronesi, P., Nolè, F., Mandalà, M., Ferretti, G., Viale, G., Goldhirsch, A. Ann. Oncol. (2002) [Pubmed]
  16. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. Curigliano, G., Ferretti, G., Flamini, G., Goldhirsch, A., de Braud, F., Calabro, M.G., Mandaly, M., Nole, F., De Pas, T., D'Addessi, A., Cittadini, A. Anticancer Res. (2001) [Pubmed]
  17. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. Curigliano, G., Ferretti, G., Mandalà, M., De Pas, T., Calabrò, M.G., Solli, P., Noberasc, C., de Braud, F. Anticancer Res. (2001) [Pubmed]
 
WikiGenes - Universities